This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Data Demonstrating Potency Of Durata Therapeutics’ Dalbavancin Against Bacterial Pathogens Presented At ICAAC 2012

Durata Therapeutics (NASDAQ: DRTX) today announced data from an in vitro study and surveillance results of its lead product candidate, dalbavancin, currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The data, presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), demonstrate the potency of dalbavancin against numerous significant bacterial isolates in the United States and Europe.

Comparative In Vitro Activity of Dalbavancin (DAL) and Other Gram-Positive Agents Against a Recent Collection of European Bacterial Isolates (Simenauer, et al). Session Number 010, Presentation Number: C2-134

Study conclusions: On a MIC 90 (Minimum Inhibitory Concentration required to inhibit the growth of 90% of organisms) basis, dalbavancin was more potent than vancomycin, linezolid or daptomycin for every organism group studied. These findings indicate that dalbavancin continues to have potent activity against target pathogens isolated in Europe. (These in vitro data were generated by Dr. Dan Sahm and his team at Eurofins Medinet, Chantilly, Va.)

Update of Dalbavancin (DAL) Activity in the USA: Report from the SENTRY Program (2011). (Jones, et al). Session Number: 010, Presentation Number: C2-138

Study conclusions: Year 2011 SENTRY Program surveillance results for dalbavancin (DAL) document sustained potent activity against Staphylococcus aureus (SA), coagulase-negative staphylococci (CoNS), beta-hemolytic streptococci (βHS), viridans gr. streptococci (VGS) and vancomycin-susceptible (VANC-S) enterococci, that averaged four-to 32-fold greater than vancomycin, daptomycin or linezolid. Further development of dalbavancin appears warranted by these in vitro potency criteria. (These in vitro data were generated from the laboratories of Dr. Ron Jones and his coauthors at the Jones Microbiology Institute Laboratories in North Liberty, Iowa.)

“These results add to the growing body of evidence that dalbavancin is a highly potent agent against the Gram-positive bacteria associated with ABSSSI and many other infections of global concern,” said Durata Chief Medical Officer Michael Dunne, M.D. “We plan to use these data and clinical trial results to support our New Drug Application with the U.S. Food and Drug Administration for dalbavancin for the treatment of ABSSSI, which we continue to anticipate submitting in the first half of 2013.”

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs